mouse anti dvl3  (Santa Cruz Biotechnology)

Journal: Bosnian Journal of Basic Medical Sciences

Article Title: Dishevelled family proteins (DVL1-3) expression in IUGR placentas

doi: 10.17305/bjbms.2020.5422

Figure Lengend Snippet: DVL1, DVL2, and DVL3 protein expression in human term placentas from normal pregnancies – control (A-C) and human term placentas from intrauterine growth restriction pregnancies (D-F). Relative versus normalized expression values of DVL1, DVL2, and DVL3 mRNA in IUGR versus control placental tissue (G) and their expression inside the individual tissue sample group (H).

Article Snippet: Primary antibodies (all from Santa Cruz Biotechnology, Dallas, TX, USA) were mouse monoclonal anti-human DVL1 (dilution 1:100, Cat No. sc-8025), rabbit polyclonal anti-human DVL2 (dilution 1:200, Cat No. sc-13974), and mouse monoclonal anti-human DVL3 (dilution 1:200, Cat No. sc-271295).

Techniques: Expressing, Control

Journal: Bosnian Journal of Basic Medical Sciences

Article Title: Dishevelled family proteins (DVL1-3) expression in IUGR placentas

doi: 10.17305/bjbms.2020.5422

Figure Lengend Snippet: Expression of DVL1, DVL2, and DVL3 proteins in term placentas from normal pregnancies and term placentas from IUGR pregnancies

Article Snippet: Primary antibodies (all from Santa Cruz Biotechnology, Dallas, TX, USA) were mouse monoclonal anti-human DVL1 (dilution 1:100, Cat No. sc-8025), rabbit polyclonal anti-human DVL2 (dilution 1:200, Cat No. sc-13974), and mouse monoclonal anti-human DVL3 (dilution 1:200, Cat No. sc-271295).

Techniques: Expressing

Journal: Bosnian Journal of Basic Medical Sciences

Article Title: Dishevelled family proteins (DVL1-3) expression in IUGR placentas

doi: 10.17305/bjbms.2020.5422

Figure Lengend Snippet: DVL3 protein expression in endothelial cells (arrows) in placental villi from normal (control) and intrauterine growth restriction pregnancies (A and C), and DVL3 protein expression in stem (arrows) and terminal villous stroma in the normal (control) and intrauterine growth restriction placentas (B and D).

Article Snippet: Primary antibodies (all from Santa Cruz Biotechnology, Dallas, TX, USA) were mouse monoclonal anti-human DVL1 (dilution 1:100, Cat No. sc-8025), rabbit polyclonal anti-human DVL2 (dilution 1:200, Cat No. sc-13974), and mouse monoclonal anti-human DVL3 (dilution 1:200, Cat No. sc-271295).

Techniques: Expressing, Control

Journal: Disease Markers

Article Title: Expression Levels and Localizations of DVL3 and sFRP3 in Glioblastoma

doi: 10.1155/2017/9253495

Figure Lengend Snippet: Percent of counted cells showing different levels of DVL3 and sFRP3 expression.

Article Snippet: Next, the primary antibodies, mouse monoclonal anti-human DVL3 (1 : 50; G-7, Santa Cruz Biotechnology Inc., Dallas, TX, USA), and rabbit polyclonal anti-human FRP3 (1 : 50; H-170, Santa Cruz Biotechnology Inc., Dallas, TX, USA) were applied for 30 min at room temperature.

Techniques: Expressing

Journal: Disease Markers

Article Title: Expression Levels and Localizations of DVL3 and sFRP3 in Glioblastoma

doi: 10.1155/2017/9253495

Figure Lengend Snippet: Demographic variables, expression levels, and localizations of DVL3 and sFRP3 proteins in glioblastoma samples. Protein intensities are represented as percent of stained cells.

Article Snippet: Next, the primary antibodies, mouse monoclonal anti-human DVL3 (1 : 50; G-7, Santa Cruz Biotechnology Inc., Dallas, TX, USA), and rabbit polyclonal anti-human FRP3 (1 : 50; H-170, Santa Cruz Biotechnology Inc., Dallas, TX, USA) were applied for 30 min at room temperature.

Techniques: Expressing, Staining

Journal: Disease Markers

Article Title: Expression Levels and Localizations of DVL3 and sFRP3 in Glioblastoma

doi: 10.1155/2017/9253495

Figure Lengend Snippet: Characteristic immunohistochemical staining of DVL3 and sFRP3 expression levels. (a) Glioblastoma showing strong cytoplasmic and nuclear staining of DVL3, (b) glioblastoma showing weak cytoplasmic staining of DVL3, (c) glioblastoma showing strong cytoplasmic and nuclear staining of sFRP3, and (d) glioblastoma showing moderate cytoplasmic and membranous staining of sFRP3 (arrow). Scale bars 50 μ m.

Article Snippet: Next, the primary antibodies, mouse monoclonal anti-human DVL3 (1 : 50; G-7, Santa Cruz Biotechnology Inc., Dallas, TX, USA), and rabbit polyclonal anti-human FRP3 (1 : 50; H-170, Santa Cruz Biotechnology Inc., Dallas, TX, USA) were applied for 30 min at room temperature.

Techniques: Immunohistochemical staining, Staining, Expressing

Journal: Disease Markers

Article Title: Expression Levels and Localizations of DVL3 and sFRP3 in Glioblastoma

doi: 10.1155/2017/9253495

Figure Lengend Snippet: Graphs demonstrating IRS of DVL3 and sFRP3 protein.

Article Snippet: Next, the primary antibodies, mouse monoclonal anti-human DVL3 (1 : 50; G-7, Santa Cruz Biotechnology Inc., Dallas, TX, USA), and rabbit polyclonal anti-human FRP3 (1 : 50; H-170, Santa Cruz Biotechnology Inc., Dallas, TX, USA) were applied for 30 min at room temperature.

Techniques:

Journal: Disease Markers

Article Title: Expression Levels and Localizations of DVL3 and sFRP3 in Glioblastoma

doi: 10.1155/2017/9253495

Figure Lengend Snippet: (a) Diagram of distribution of cells with strong DVL3 signal regarding localization (C and C+N). The graphs showing Wilcox rank of W = 241 and P value P = 6.33 × 10 −5 . ∗∗∗ denotes statistical significance. (b) Diagram of distribution of cells with strong sFRP3 signal regarding localization (C+M and C+M+N). The graphs showing Wilcox rank of W = 144 and P value P = 0.1903.

Article Snippet: Next, the primary antibodies, mouse monoclonal anti-human DVL3 (1 : 50; G-7, Santa Cruz Biotechnology Inc., Dallas, TX, USA), and rabbit polyclonal anti-human FRP3 (1 : 50; H-170, Santa Cruz Biotechnology Inc., Dallas, TX, USA) were applied for 30 min at room temperature.

Techniques: